Annual EBITDA
-$7.69 M
+$3.37 M+30.49%
31 December 2023
Summary:
Hoth Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$7.69 million, with the most recent change of +$3.37 million (+30.49%) on 31 December 2023. During the last 3 years, it has fallen by -$391.30 thousand (-5.36%). HOTH annual EBITDA is now -208.39% below its all-time high of -$2.49 million, reached on 31 December 2018.HOTH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.13 M
-$486.50 K-29.56%
30 September 2024
Summary:
Hoth Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.13 million, with the most recent change of -$486.50 thousand (-29.56%) on 30 September 2024. Over the past year, it has dropped by -$39.30 thousand (-1.88%). HOTH quarterly EBITDA is now -304.46% below its all-time high of -$527.20 thousand, reached on 31 March 2018.HOTH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$7.53 M
-$39.30 K-0.52%
30 September 2024
Summary:
Hoth Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$7.53 million, with the most recent change of -$39.30 thousand (-0.52%) on 30 September 2024. Over the past year, it has increased by +$1.89 million (+20.02%). HOTH TTM EBITDA is now -1328.32% below its all-time high of -$527.20 thousand, reached on 31 March 2018.HOTH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HOTH EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.5% | -1.9% | +20.0% |
| 3 y3 years | -5.4% | +34.5% | +34.7% |
| 5 y5 years | -208.4% | -25.4% | -71.9% |
HOTH EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -5.4% | +45.5% | -29.6% | +37.7% | -0.5% | +46.6% |
| 5 y | 5 years | -208.4% | +45.5% | -165.6% | +50.0% | -71.9% | +46.6% |
| alltime | all time | -208.4% | +45.5% | -304.5% | +50.0% | -1328.3% | +46.6% |
Hoth Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.13 M(+29.6%) | -$7.53 M(+0.5%) |
| June 2024 | - | -$1.65 M(-19.9%) | -$7.49 M(-0.8%) |
| Mar 2024 | - | -$2.05 M(+21.0%) | -$7.55 M(-1.8%) |
| Dec 2023 | -$7.69 M(-30.5%) | -$1.70 M(-18.9%) | -$7.69 M(-18.3%) |
| Sept 2023 | - | -$2.09 M(+22.5%) | -$9.42 M(-5.9%) |
| June 2023 | - | -$1.71 M(-22.1%) | -$10.01 M(-5.6%) |
| Mar 2023 | - | -$2.19 M(-35.9%) | -$10.60 M(-4.2%) |
| Dec 2022 | -$11.07 M(-21.5%) | -$3.42 M(+27.4%) | -$11.07 M(+0.4%) |
| Sept 2022 | - | -$2.68 M(+16.7%) | -$11.02 M(-4.9%) |
| June 2022 | - | -$2.30 M(-13.6%) | -$11.59 M(-7.2%) |
| Mar 2022 | - | -$2.66 M(-21.3%) | -$12.49 M(-11.4%) |
| Dec 2021 | -$14.10 M | -$3.38 M(+3.9%) | -$14.10 M(+22.4%) |
| Sept 2021 | - | -$3.25 M(+1.7%) | -$11.52 M(+10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$3.20 M(-25.1%) | -$10.44 M(+7.0%) |
| Mar 2021 | - | -$4.27 M(+431.8%) | -$9.75 M(+33.6%) |
| Dec 2020 | -$7.30 M(-5.4%) | -$802.80 K(-62.9%) | -$7.30 M(-29.9%) |
| Sept 2020 | - | -$2.17 M(-13.9%) | -$10.42 M(+4.7%) |
| June 2020 | - | -$2.52 M(+38.5%) | -$9.95 M(+14.3%) |
| Mar 2020 | - | -$1.82 M(-53.6%) | -$8.70 M(+12.8%) |
| Dec 2019 | -$7.71 M(+209.3%) | -$3.92 M(+130.4%) | -$7.71 M(+76.1%) |
| Sept 2019 | - | -$1.70 M(+34.2%) | -$4.38 M(+32.7%) |
| June 2019 | - | -$1.27 M(+52.9%) | -$3.30 M(+18.0%) |
| Mar 2019 | - | -$829.10 K(+42.0%) | -$2.80 M(+12.1%) |
| Dec 2018 | -$2.49 M | -$584.00 K(-5.8%) | -$2.49 M(+30.6%) |
| Sept 2018 | - | -$619.90 K(-18.8%) | -$1.91 M(+48.0%) |
| June 2018 | - | -$763.10 K(+44.7%) | -$1.29 M(+144.7%) |
| Mar 2018 | - | -$527.20 K | -$527.20 K |
FAQ
- What is Hoth Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Hoth Therapeutics?
- What is Hoth Therapeutics annual EBITDA year-on-year change?
- What is Hoth Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Hoth Therapeutics?
- What is Hoth Therapeutics quarterly EBITDA year-on-year change?
- What is Hoth Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Hoth Therapeutics?
- What is Hoth Therapeutics TTM EBITDA year-on-year change?
What is Hoth Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of HOTH is -$7.69 M
What is the all time high annual EBITDA for Hoth Therapeutics?
Hoth Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$2.49 M
What is Hoth Therapeutics annual EBITDA year-on-year change?
Over the past year, HOTH annual earnings before interest, taxes, depreciation & amortization has changed by +$3.37 M (+30.49%)
What is Hoth Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of HOTH is -$2.13 M
What is the all time high quarterly EBITDA for Hoth Therapeutics?
Hoth Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$527.20 K
What is Hoth Therapeutics quarterly EBITDA year-on-year change?
Over the past year, HOTH quarterly earnings before interest, taxes, depreciation & amortization has changed by -$39.30 K (-1.88%)
What is Hoth Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of HOTH is -$7.53 M
What is the all time high TTM EBITDA for Hoth Therapeutics?
Hoth Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$527.20 K
What is Hoth Therapeutics TTM EBITDA year-on-year change?
Over the past year, HOTH TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.89 M (+20.02%)